|
AU2020402006A1
(en)
*
|
2019-12-12 |
2022-07-07 |
Jiangsu Hengrui Medicine Co., Ltd. |
Anti-claudin antibody-drug conjugate and pharmaceutical use thereof
|
|
CA3186295A1
(en)
*
|
2020-06-08 |
2021-12-16 |
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. |
Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof
|
|
WO2021252708A1
(en)
*
|
2020-06-11 |
2021-12-16 |
President And Fellows Of Harvard College |
Stabilized trioxacarcin antibody drug conjugates and uses thereof
|
|
EP4227309A4
(en)
*
|
2020-10-12 |
2024-11-27 |
Sichuan Baili Pharmaceutical Co. Ltd. |
DEUTERATED CAMPTOTHECIN DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF
|
|
EP4257153B1
(en)
*
|
2020-12-04 |
2025-11-12 |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. |
Antibody-drug conjugate, and intermediate thereof, preparation method therefor, and application thereof
|
|
US20230416270A1
(en)
*
|
2020-12-11 |
2023-12-28 |
Wigen Biomedicine Technology (shanghai) Co., Ltd. |
Novel camptothecin derivative, composition comprising same and use thereof
|
|
EP4265274B1
(en)
*
|
2020-12-18 |
2025-03-19 |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. |
B7-h3 targeting antibody-drug conjugate, and preparation method therefor and use thereof
|
|
KR20230121842A
(ko)
*
|
2020-12-18 |
2023-08-21 |
상하이 후단-장지앙 바이오-파마슈티컬 컴퍼니 리미티드 |
Trop2를 표적으로 하는 항체 약물 접합체, 이의 제조방법 및 용도
|
|
CN114805377A
(zh)
*
|
2021-01-29 |
2022-07-29 |
明慧医药（杭州）有限公司 |
适用于抗体-药物偶联物的毒素分子
|
|
CN116888123B
(zh)
*
|
2021-02-09 |
2026-02-24 |
微境生物医药科技(上海)有限公司 |
用于adc制备的喜树碱衍生物
|
|
CN116897149A
(zh)
*
|
2021-03-30 |
2023-10-17 |
上海复旦张江生物医药股份有限公司 |
一种连接基药物偶联物的制备方法及其中间体
|
|
WO2022205111A1
(zh)
*
|
2021-03-31 |
2022-10-06 |
上海复旦张江生物医药股份有限公司 |
一种伊喜替康衍生物的制备方法及其中间体
|
|
CN115385926B
(zh)
*
|
2021-05-24 |
2025-06-03 |
上海复旦张江生物医药股份有限公司 |
一种连接基药物偶联物的制备方法及其中间体
|
|
JP2024523422A
(ja)
*
|
2021-06-17 |
2024-06-28 |
ミンフイ ファーマシューティカル （ハンチョウ） リミテッド |
抗腫瘍化合物およびその応用
|
|
TW202320858A
(zh)
|
2021-07-19 |
2023-06-01 |
美商薩諾管理公司 |
免疫接合物及方法
|
|
US11806405B1
(en)
|
2021-07-19 |
2023-11-07 |
Zeno Management, Inc. |
Immunoconjugates and methods
|
|
CN117715913A
(zh)
*
|
2021-07-19 |
2024-03-15 |
芝诺管理公司 |
免疫缀合物和方法
|
|
KR20240040090A
(ko)
|
2021-07-30 |
2024-03-27 |
상하이 후단-장지앙 바이오-파마슈티컬 컴퍼니 리미티드 |
항-dll3 항체 및 이의 제조 방법, 이의 약물 접합체 및 용도
|
|
WO2023042097A1
(en)
*
|
2021-09-15 |
2023-03-23 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate for use in methods of treating chemotherapy-resistant cancer
|
|
AU2022350588A1
(en)
*
|
2021-09-27 |
2024-05-02 |
Evopoint Biosciences Co., Ltd. |
Antibody, antibody-drug conjugate thereof and use thereof
|
|
CN118401258A
(zh)
*
|
2021-12-09 |
2024-07-26 |
昆山新蕴达生物科技有限公司 |
一种亲和力改善的抗体-药物偶联物、其制备方法及应用
|
|
KR20250009592A
(ko)
|
2022-04-12 |
2025-01-17 |
미네르바 바이오테크놀로지 코포레이션 |
항-가변 muc1* 항체 및 그의 용도
|
|
CN118955615B
(zh)
*
|
2022-07-05 |
2026-01-30 |
上海药明合联生物技术有限公司 |
偶联连接子
|
|
EP4558506A1
(en)
*
|
2022-07-22 |
2025-05-28 |
NJ Bio, Inc. |
Hexacyclic topoisomerase inhibitors having cytotoxic activity on cancer cells
|
|
EP4562051A1
(en)
*
|
2022-07-26 |
2025-06-04 |
Immunome, Inc. |
Immunoconjugates and methods
|
|
KR20250049293A
(ko)
*
|
2022-07-27 |
2025-04-11 |
밍훼이 파마슈티컬 (항저우) 리미티드 |
항체-약물 접합체 및 이의 용도
|
|
CN117510515A
(zh)
*
|
2022-07-28 |
2024-02-06 |
明慧医药（杭州）有限公司 |
适用于抗体-药物偶联物的毒素分子
|
|
CN120417935A
(zh)
*
|
2022-10-25 |
2025-08-01 |
默沙东有限责任公司 |
依喜替康衍生的adc接头-载荷及其药物组合物和用途
|
|
EP4623936A1
(en)
*
|
2022-11-22 |
2025-10-01 |
Keymed Biosciences (Chengdu) Co., Ltd. |
Fused ring compound, conjugate thereof and use thereof
|
|
KR20250111373A
(ko)
*
|
2022-11-25 |
2025-07-22 |
밍훼이 파마슈티컬 (항저우) 리미티드 |
항종양 화합물 및 이의 응용
|
|
TW202426059A
(zh)
*
|
2022-11-30 |
2024-07-01 |
大陸商正大天晴藥業集團股份有限公司 |
抗cldn18.2抗體藥物偶聯物及其藥物組合物和用途
|
|
CN116217654B
(zh)
*
|
2022-12-30 |
2025-09-26 |
上海复旦张江生物医药股份有限公司 |
一种连接基药物偶联物的制备方法及其中间体
|
|
CN116217655B
(zh)
*
|
2022-12-30 |
2025-09-23 |
上海复旦张江生物医药股份有限公司 |
一种连接基药物偶联物的中间体的制备方法
|
|
CN116178386B
(zh)
*
|
2022-12-30 |
2025-09-09 |
上海复旦张江生物医药股份有限公司 |
一种连接基药物偶联物的制备方法及其中间体
|
|
EP4696332A1
(en)
|
2023-04-10 |
2026-02-18 |
Daiichi Sankyo Company, Limited |
Combination of anti-b7-h3 antibody-drug conjugate with atr inhibitor or atm inhibitor
|
|
WO2025021152A1
(zh)
*
|
2023-07-26 |
2025-01-30 |
上海医药集团股份有限公司 |
喜树碱类小分子及其抗体药物偶联物、制备方法和应用
|
|
WO2025049270A1
(en)
*
|
2023-08-25 |
2025-03-06 |
Macrogenics, Inc. |
B7-h3 antibody-drug conjugates
|
|
WO2025106278A1
(en)
|
2023-11-17 |
2025-05-22 |
Mersana Therapeutics, Inc. |
Treatment of cancer using b7-h4-targeted antibody-drug conjugates
|
|
WO2025238587A1
(en)
|
2024-05-16 |
2025-11-20 |
Daiichi Sankyo Company, Limited |
Combination of anti-b7-h3 antibody-drug conjugate and androgen receptor signaling inhibitor
|
|
CN120617538B
(zh)
*
|
2025-07-21 |
2026-04-03 |
南京滴力生物科技有限公司 |
一种用于治疗肿瘤的抗体药物偶联物
|